Sacubitril/Valsartan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Sacubitril/Valsartan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
373
Registered trials
177
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Sacubitril/Valsartan can convert its Small molecule drug profile and AT1R x CD10 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Sacubitril/Valsartan (query alias: sacubitril valsartan) |
|---|---|
| Modality / target | Small molecule drug; AT1R x CD10; AT1R antagonists, enkephalinase inhibitors |
| Highest global status | Approved |
| Originator | Novartis Pharma AG |
| Active developers | Novartis AG, Novartis Europharm Ltd., Novartis Pharma Schweiz AG |
The MCP disease footprint includes Essential Hypertension, Hypertension, Left ventricular systolic dysfunction. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| CTR20262158 | Not Applicable | 进行中 （尚未招募） | 42 | Not disclosed |
| CTR20262264 | Not Applicable | 进行中 （尚未招募） | 34 | Not disclosed |
| CTR20262432 | Not Applicable | 进行中 （尚未招募） | Not disclosed | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint, Phase 4 Study to Evaluate the Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With Chronic Chagas' Cardiomyopathy. The Study is Also Know as Prevention And Reduction of Adverse Outcomes in Chagasic Heart failUre Trial Evaluation (PARACHUTE-HF).
Phase 4; n=922; evaluation: not stated. Reported fields: -; Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From Baseline to Week 12 = 103086 wins ; Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From Baseline to Week 12 = 67097 wins
The FUNCTION Study: A Randomized Controlled Trial on the Efficacy of Sacubitril/Valsartan on the Success Rate of Catheter Ablation for Nonparoxysmal Atrial Fibrillation
Early Phase 1; n=240; evaluation: Positive. Reported fields: Left atrial diameter: adjusted mean difference = -1.9(95.0% CI, -3.2 to -0.5), P-Value = 0.02; Left atrial diameter: adjusted mean difference = -1.9(95.0% CI, -3.2 to -0.5), P-Value = 0.02
Uptitration of Sacubitril/Valsartan in Acute Heart Failure: Insight from the PREMIER Study
Phase 4; n=376; evaluation: Positive. Reported fields: NT-proBNP = -39.0 % ; NT-proBNP = -51.0 % ; NT-proBNP = -32.0 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Sacubitril/Valsartan addresses Essential Hypertension, Hypertension, Left ventricular systolic dysfunction. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2020-02-29 | Otsuka enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan | Approved | US$92.7M upfront |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Stable oral pharmaceutical compositions comprising sacubitril & valsartan hydrate”. The milestone feed surfaced a patent-application signal described as “Stable oral pharmaceutical compositions comprising sacubitril; valsartan”. The milestone feed surfaced a patent-application signal described as “Sacubitril valsartan sodium sustained-release composition, and preparation method therefor and use thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
